Please ensure Javascript is enabled for purposes of website accessibility

Why Did Karuna Therapeutics Pop 26% in January?

By Taylor Carmichael - Feb 5, 2020 at 10:35AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The volatile biotech has been up and down since its massive gain back in November.

What happened

Shares of Karuna Therapeutics (KRTX 0.44%) rose 26% in January, according to data provided by S&P Global Market Intelligence. However, at $92 a share as of this writing, the stock is still below its all-time high of $124 a share, set less than three months ago.

Karuna had a spectacular 2019. Though it did drop below its offering price at one point, the stock had a massive gain late last year, right after the company announced positive results from its phase 2 trial for its schizophrenia drug, KarXT. Investors saw the value of their shares multiply by seven times in a matter of days. The giant move made Karuna the top IPO stock for 2019.

There hasn't been any medical news that's been rocking the share price in 2020, but it's been a volatile ride all the same. The stock shot up on Jan. 10 to close at $72.17 and rose to $115.92 on Jan. 22. On Feb. 4, it closed at $93.02 per share. It looks like some early investors have been taking profits, and new investors are making buys as they discover the pharmaceutical stock.   

an image from a brain scan

Image source: Getty Images.

So what

What's got investors interested? Well, about 20 million people worldwide suffer from schizophrenia. According to Fortune Business Insights, the schizophrenia drug market was valued at $6.75 billion in 2018, and is estimated to reach $9.48 billion by 2026. One of the leading drugs is the antipsychotic Invega Sustenna from Johnson & Johnson, and it and related products were on pace to reach a combined $3.4 billion in sales in 2019.

Karuna's drug targets a different area of the brain, and is expected to work on schizophrenia patients that are not helped by current antipsychotic medicines. In its phase 2 trial, the drug had a statistically significant 11.6-point improvement on PANSS (positive and negative syndrome scale) versus placebo. 

Now what

Karuna plans on initiating its phase 3 trial before the end of 2020. The company is testing KarXT in other indications as well, including psychosis from Alzheimer's, as well as cognitive symptoms from schizophrenia and negative symptoms from schizophrenia. The company believes that its drug compares favorably with antipsychotic drugs that peaked at $5 billion in annual sales.     

While KarXT is very promising, probably the earliest the company can hope to have its drug on the market is late 2022. However, paying for its phase 3 trial will not be a problem. Karuna issued a secondary offering after its successful phase 2 trial, raising $250 million. The company now has $412 million in cash and no debt.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Karuna Therapeutics, Inc. Stock Quote
Karuna Therapeutics, Inc.
$104.53 (0.44%) $0.46

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.